Disc Medicine, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of treatments for serious hematologic diseases. The company targets fundamental biological pathways associated with red blood cell formation and function, specifically heme biosynthesis and iron homeostasis. Its lead product candidate, bitopertin, is a glycine transporter 1 inhibitor being developed for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria and X-linked protoporphyria. The company’s iron homeostasis portfolio includes DISC-0974, a hepcidin suppressor licensed from AbbVie for anemia of myelofibrosis and inflammatory bowel disease, and DISC-3405, a monoclonal antibody against TMPRSS6 licensed from Mabwell Therapeutics for polycythemia vera and sickle cell disease. A preclinical program, DISC-0998, is also being developed for anemia associated with inflammatory diseases. Clinical trials have been conducted in the United States and Australia, with regulatory submissions made to the U.S. Food and Drug Administration.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage discmedicine.com
Sector Healthcare IR page ir.discmedicine.com
Tags
hematologic diseases, heme biosynthesis, iron homeostasis, erythropoietic porphyrias, anemia, polycythemia vera, sickle cell disease, monoclonal antibodies, glycine transporter 1 inhibitors, bitopertin, DISC-0974, DISC-3405, DISC-0998, BEACON, AURORA, HELIOS, APOLLO, RALLY-MF, RESTORE-PV
Press page —

Metrics

Valuation  
Market cap $ 3.286B
Market cap (USD) $ 3.286B
P/E -13.38
PEG —
P/BV 5.44
P/S —
P/OCF -17.30
P/FCF -17.30
Dividend yield —
Turnover / mcap —
Returns  
ROE -35.9%
ROI -27.6%
ROIC -23.0%
Profit margin —
Growth  
Revenue growing —
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 9.9%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 26
Quality score -69.2%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Assets 806.879M 496.773M 367.996M 200.205M 140.437M 122.093M
Net profit -212.184M -109.357M -76.429M -46.827M -71.869M —
Free cash flow -181.326M -94.431M -73.551M -42.403M -59.771M —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Share price 79.41 63.4 57.76 19.89 — —
Price performance 12m 0.25 0.1 1.9 — — —

Filed figures

Figure Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Borrowings, current (USD) — 11.7M — — — — —
Lease liabilities (USD) — — 1.65M 1.33M 2.1M 1.68M 1.86M
Cash and deposits (USD) 3.31M 1.21M 137M 195M 360M 192M 91.1M
Right-of-use assets (USD) — — 1.64M 1.43M 1.93M 1.57M 1.1M
Net debt (borrowings + leases - cash) (USD) — 7.19M — — — — —
Cash flow detail
Operating cash flow (USD) — -32.7M -59.7M -42.3M -73.5M -93.9M -180M
Purchases of property, plant and equipment (USD) — -22,000 -71,000 -151,000 -89,000 -505,000 -933,000
Change in payables (cash effect) (USD) — -2.41M 1.56M 526,000 -3.74M -4.68M 1.07M
Interest paid (cash effect) (USD) — -345,000 -307,000 — 0.00 -198,000 -2.8M
Income taxes paid (cash effect) (USD) — — 0.00 0.00 -112,000 -299,000 -349,000
Share-based compensation (USD) — 983,000 7.79M 2.09M 5.53M 16.8M 34.3M
Free cash flow (OCF - PPE - intangibles) (USD) — -32.7M -59.8M -42.4M -73.6M -94.4M -181M
Income detail
Research and development expense (USD) — 28.2M 48.7M 33.4M 69.3M 96.7M 171M
↳ 5y CAGR +43.4%
Total comprehensive income (USD) — — — — -76.4M -109M -212M
Comprehensive income to owners (USD) — — — — -76.4M -109M -212M
Reported May 13, 2021 Mar 10, 2022 Mar 31, 2023 Mar 31, 2023 Feb 27, 2025 Feb 27, 2025 Feb 26, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

November 5, 2026

PDF Version

  • Pivotal Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria (EPP) successfully met all primary and secondary endpoints

  • Bitopertin NDA resubmission planned by end of 2026, with an FDA decision for potential approval in EPP anticipated by mid-2027

  • Feedback from the upcoming end of phase 2 meeting with the FDA on selcodebart in anemia of myelofibrosis (MF) and plans for pivotal development in anemia of MF to be announced by the end of the year

  • Presented positive initial results from the Phase 2 RESTORE-PV study of DISC-3405 in polycythemia vera (PV)

  • Updated data from RESTORE-PV and initial data from a Phase 1b study of DISC-3405 in sickle cell disease (SCD) to be presented at the 68th American Society of Hematology (ASH) annual meeting in December 2026

  • Strong financial position ending Q3 with approximately $683 million in cash, cash equivalents, and marketable securities; completed a public offering in October 2026, with net proceeds of approximately $486 million extending cash runway into 2030

WATERTOWN, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today reported financial results for the third quarter ended September 30, 2026, and provided a review of recent program and corporate developments.

“In our first pivotal trial readout as a company, APOLLO delivered strong and compelling evidence of the potential clinical benefit of bitopertin for patients with EPP,” said John Quisel, J.D., Ph.D., President and Chief Executive Officer of Disc. “We look forward to engaging with regulators with the goal of bringing an important, innovative medicine to this community as efficiently as possible.”

“We also made significant progress across our broader pipeline, including encouraging initial RESTORE-PV data that reinforce the potential of DISC-3405 to maintain target hematocrit levels and improve symptoms for patients with polycythemia vera,” Dr. Quisel added. “Alongside our anticipated end-of-Phase 2 FDA meeting for selcodebart in anemia of myelofibrosis in the fourth quarter and a strengthened balance sheet, we are well positioned to support the anticipated launch of bitopertin and advance two additional programs toward pivotal-stage development in 2027.”

Recent Highlights and Anticipated Milestones:

Bitopertin: GlyT1 Inhibitor (Heme Synthesis Modulator)

  • Positive topline data from the Phase 3 APOLLO clinical trial of bitopertin in EPP achieved statistical significance on both co-primary endpoints of reduction in whole blood metal-free PPIX from baseline and average monthly total time in sunlight without pain during month 6 of treatment vs. placebo. The data showed:

  • Bitopertin reduced whole-blood metal-free PPIX by 41.4% versus placebo (p<0.0001) and increased average monthly total time in light without pain by 12.2 hours during month 6 (p=0.0010)

  • Positive and statistically significant results from all secondary endpoints, including reductions in phototoxic reactions and improvements on multiple measures of light tolerance. Exploratory endpoints of quality-of-life benefits were also positive and statistically significant.

  • Bitopertin was generally well-tolerated. Consistent with prior studies, dizziness was the most commonly reported treatment emergent adverse event (TEAE) in the bitopertin group (50%) and was mild or moderate and generally transient. There were no TEAEs above Grade 3.

  • Successful APOLLO results add to bitopertin’s robust clinical data package. Based on these results, Disc plans to resubmit a New Drug Application (NDA) to the U.S. FDA by the end of 2026, with a decision from the agency anticipated by mid-2027

Selcodebart (DISC-0974): Anti-Hemojuvelin Antibody (Hepcidin Suppression)

  • Updated data from the RALLY-MF trial to be presented at ASH in December

  • Feedback from an end of phase 2 meeting with the FDA and plans for pivotal development in anemia of MF to be announced by the end of the year

  • Progressing Phase 2 study of selcodebart in patients with inflammatory bowel disease (IBD) with initial data expected in 2027

DISC-3405: Anti-TMPRSS6 Antibody (Hepcidin Induction)

  • Presented positive initial results from the RESTORE-PV Phase 2 clinical trial of DISC-3405 in patients with PV at the SOHO Annual Meeting. Efficacy data was presented for the Q2 weekly dosed cohort. Across escalation and maintenance periods, results demonstrated:

  • DISC-3405 increased hepcidin and lowered serum iron, translating to controlled hematocrit, reduced phlebotomy, and improved symptoms in PV patients

  • Generally well-tolerated with adverse events that are consistent with underlying disease and a low rate of injection site reactions which were mild and self-limited

  • Updated data from RESTORE-PV, including initial efficacy data on the Q4 weekly dosed cohort, to be presented at ASH in December

  • Initial data from Phase 1b study of DISC-3405 in patients with sickle cell disease also to be presented at ASH

Third Quarter 2026 Financial Results:

  • **Cash Position:**Cash, cash equivalents, and marketable securities were $682.8 million as of September 30, 2026. In October 2026, Disc completed a public offering with net proceeds of approximately $485.9 million. Together with such net proceeds, we believe that our cash, cash equivalents, and marketable securities will be sufficient to fund our current operating and capital expenditure plans and our debt service obligations into 2030.

  • Research and Development Expenses: R&D expenses were $44.1 million for the three months ended September 30, 2026, as compared to $50.3 million for the three months ended September 30, 2025. The decrease in R&D expenses was primarily driven by a $10.0 million milestone payment and drug manufacturing in the comparative period that did not recur in the current period. These decreases were partially offset by increased investment across our development portfolio, including higher personnel-related costs driven by increased headcount.

  • **Selling, General and Administrative Expenses:**SG&A expenses were $20.1 million for the three months ended September 30, 2026, as compared to $17.4 million for the three months ended September 30, 2025. The increase in SG&A expenses was primarily due to increased headcount.

  • **Net Loss:**Net loss was $59.5 million for the three months ended September 30, 2026, as compared to $62.3 million for the three months ended September 30, 2025. The decrease was primarily due to lower research and development expenses resulting from costs incurred in the prior-year period that did not recur in the current period, partially offset by continued investment in advancing our pipeline and higher personnel-related costs.

About Disc Medicine

Disc Medicine (NASDAQ:IRON) is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. For more information, please visit www.discmedicine.com.

Available Information

Disc announces material information to the public about the Company, its products and services, and other matters through a variety of means, including filings with the U.S. Securities and Exchange Commission (SEC), press releases, public conference calls, webcasts and the investor relations section of the Company website at ir.discmedicine.com in order to achieve broad, non-exclusionary distribution of information to the public and for complying with its disclosure obligations under Regulation FD.

Disc Cautionary Statement Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, express or implied statements regarding: Disc’s expectations with respect to the next stages of its development programs for bitopertin, selcodebart (DISC-0974) and DISC-3405, including projected timelines for the initiation and completion of its clinical trials, anticipated timing of release of data, and other clinical activities; the registrational pathway for bitopertin, including the potential timeline for an NDA resubmission and the timing of an FDA decision; anticipated discussions with regulatory agencies; the potential launch and commercialization of bitopertin, if approved; and the strength of its financial position and its anticipated cash runway. The use of words such as, but not limited to, “believe,” “expect,” “estimate,” “project,” “intend,” “future,” “potential,” “continue,” “may,” “might,” “plan,” “will,” “should,” “seek,” “anticipate,” or “could” or the negative of these terms and other similar words or expressions that are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on Disc’s current beliefs, expectations and assumptions regarding the future of Disc’s business, future plans and strategies, clinical results and other future conditions. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Disc may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and investors should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements as a result of a number of material risks and uncertainties including but not limited to: the adequacy of Disc’s capital to support its future operations and its ability to successfully initiate and complete clinical trials; the nature, strategy and focus of Disc; the difficulty in predicting the time and cost of development of Disc’s product candidates; Disc’s plans to research, develop and commercialize its current and future product candidates; the timing of initiation of Disc’s planned preclinical studies and clinical trials; the timing of the availability of data from Disc’s clinical trials; Disc’s ability to identify additional product candidates with significant commercial potential and to expand its pipeline in hematological diseases; the timing and anticipated results of Disc’s preclinical studies and clinical trials and the risk that the results of Disc’s preclinical studies and clinical trials may not be predictive of future results in connection with future studies or clinical trials and may not support further development and marketing approval; the content and timing of decisions made by the FDA and other regulatory authorities; and the other risks and uncertainties described in Disc’s filings with the Securities and Exchange Commission, including in the “Risk Factors” section of Disc’s Annual Report on Form 10-K for the year ended December 31, 2025, and in subsequent Quarterly Reports on Form 10-Q. Any forward-looking statement speaks only as of the date on which it was made. None of Disc, nor its affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as result of new information, future events or otherwise, except as required by law.

Media Contact

Peg Rusconi Deerfield Group [email protected]

Investor Relations Contact

Kevin Lui Precision AQ [email protected]

| DISC MEDICINE, INC. |

| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS |

| (In thousands, except share and per share amounts) |

| (Unaudited) |

| |

| | ​ | Three months ended September 30, | | Nine Months Ended September 30, |

| | ​ | | 2026 | | ​ | | 2025 | | ​ | | 2026 | | ​ | | 2025 | |

| Operating expenses: | ​ | | ​ | | ​ | | ​ | |

| Research and development | ​ | $ | 44,080 | | | $ | 50,334 | | | $ | 136,917 | | | $ | 124,416 | |

| Selling, general and administrative | ​ | | 20,081 | | | | 17,362 | | | | 61,843 | | | | 44,636 | |

| Total operating expenses | ​ | | 64,161 | | ​ | | 67,696 | | ​ | | 198,760 | | ​ | | 169,052 | |

| Loss from operations | ​ | | (64,161 | ) | ​ | | (67,696 | ) | ​ | | (198,760 | ) | ​ | | (169,052 | ) |

| Other income (expense), net | | | 4,735 | | ​ | | 5,477 | | ​ | | 16,418 | | ​ | | 17,672 | |

| Income tax expense | ​ | | (109 | ) | | | (102 | ) | | | (229 | ) | | | (273 | ) |

| Net loss | ​ | $ | (59,535 | ) | ​ | $ | (62,321 | ) | ​ | $ | (182,571 | ) | ​ | $ | (151,653 | ) |

| Net loss per share, basic and diluted | ​ | $ | (1.53 | ) | ​ | $ | (1.77 | ) | ​ | $ | (4.72 | ) | ​ | $ | (4.39 | ) |

| Weighted-average common shares outstanding, basic and diluted | ​ | | 38,904,676 | | | | 35,178,691 | | | | 38,695,405 | | | | 34,516,134 | |

| | | | | | | | | |

| | | | | | | | | |

| DISC MEDICINE, INC. | |

| CONDENSED CONSOLIDATED BALANCE SHEETS | |

| (In thousands) | |

| | | | | | | |

| | ​ | September 30, 2026 | | December 31, 2025 |

| | | (Unaudited) | | | |

| Assets | ​ | | | | | |

| Cash, cash equivalents, and marketable securities | ​ | $ | 682,816 | | | $ | 791,152 | |

| Other current assets | ​ | | 14,589 | | | | 12,746 | |

| Total current assets | ​ | | 697,405 | | | | 803,898 | |

| Non-current assets | ​ | | 2,083 | | | | 2,981 | |

| Total assets | ​ | $ | 699,488 | | | $ | 806,879 | |

| Liabilities and Stockholders’ Equity | ​ | | | | | |

| Current liabilities | ​ | $ | 34,360 | | | $ | 36,641 | |

| Non-current liabilities | ​ | | 60,878 | | | | 30,412 | |

| Total liabilities | ​ | | 95,238 | | | | 67,053 | |

| Total stockholders’ equity | ​ | | 604,250 | | | | 739,826 | |

| Total liabilities and stockholders’ equity | ​ | $ | 699,488 | | | $ | 806,879 | |

| | | | | | | | | |

Disc Medicine

Privacy Preference Center

Privacy Preference Center

  • Your Privacy

  • Required Cookies

  • Functional and Analytics Cookies

  • Targeting and Social Media Cookies

Your Privacy

We and our affiliates and vendors use cookies and similar technologies to enhance site navigation, analyze site usage, and assist in our marketing efforts, including sharing data with third parties for advertising purposes. Click Accept All to accept all cookies, click Reject All to reject all but those cookies strictly necessary to the functioning of the site (required cookies) and to opt-out of the sale and sharing of your data, or click Manage Preferences to choose your cookie preferences. For more information, see our Privacy Notice. Cookie Notice.

Required Cookies

Always Active

These cookies are considered “required” for the regular operation and security of our Online Services, as well as for the provision of the services and products you request. Without these cookies, we will not be able to provide certain core features of our Online Services, such as loading images and allowing you to select your cookie preferences. These cookies do not store any personal information. For these cookies, we do not ask for your consent, but we do inform you about their presence on our Online Services.

Functional and Analytics Cookies

Functional and Analytics Cookies

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. They may be set by us or by third party service providers whose services we have added to our pages. These cookies may also measure how you interact with content on our Online Services, which helps us improve our Online Services and your experience. If you reject these cookies, then some or all of these services may not function properly, and we will not know when you have visited our site and will not be able to monitor its performance.

Targeting and Social Media Cookies

Targeting and Social Media Cookies

Targeting cookies may be set through our advertising partners and used by them to build a profile of your interests and show you more relevant advertisements on other sites. Disabling these types of cookies will not opt you out of being served ads. You may continue to receive non-targeted ads. Social Media cookies are capable of tracking your browser across other sites and building a profile of your interests. This may impact the content and messages you see on other websites you visit. Under certain laws, you have the right to opt out of the sale of your personal data to third parties. You also have the right to opt out of targeted advertising. You may exercise your right to opt out of the sale of your personal data and of targeted advertising via cookies and tracking technologies here, or by enabling a global opt-out signal as described below. If you opt out, we will not be able to offer you personalized ads, and we will stop sharing your personal data with social media partners. If you do not allow these cookies you may not be able to use or see these sharing tools. For more information on your privacy rights, contact us as indicated below.

Cookie List

Leg.Interest

checkbox label label

checkbox label label

checkbox label label

Clear

  • checkbox label label

Apply Cancel

Reject All Cookies Allow All Cookies

Powered by Onetrust

November 4, 2026

PDF Version

  • Two oral presentations featuring additional data from RALLY-MF Phase 2 trial of selcodebart (DISC-0974) in anemia of myelofibrosis (MF) and RESTORE-PV Phase 2 trial of DISC-3405 in polycythemia vera (PV)

  • Oral presentation highlighting inhibition of glycine transporter 1 reduced chronic inflammation and improved red blood cell health in a mouse model of erythropoietic protoporphyria (EPP)

  • Poster presentations across all programs, including initial data from Phase 1b trial of DISC-3405 in sickle cell disease (SCD), baseline characteristics from Phase 3 APOLLO trial of bitopertin in EPP, and new translational data in preclinical models supporting use in existing and additional indications

  • Management will host a conference call following the ASH meeting on Wednesday, December 16 at 8:00am EST

WATERTOWN, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that it will present data from multiple programs in its portfolio at the upcoming American Society of Hematology (ASH) Annual Meeting, which will be held in New Orleans, LA on December 12-15, 2026.

“Following highly successful Phase 3 APOLLO topline results for our lead program, bitopertin in EPP, we are eager to share the growing breadth of evidence across our portfolio. At ASH 2026, we look forward to presenting clinical updates from our ongoing Phase 2 trials in MF anemia and PV, new translational findings that further support bitopertin’s potential in EPP, and initial data from our Phase 1b trial in SCD,” said John Quisel, J.D., Ph.D., President and Chief Executive Officer at Disc Medicine. “Collectively, these data reinforce the momentum across our pipeline and position us for a next phase of growth as we work to bring transformative therapies to patients with serious hematologic disorders.”

Management will host a call following the ASH meeting to review highlights of the presented data and plans for next steps in development on Wednesday, December 16 at 8:00am EST. Please register for the event on the Events and Presentations page of Disc’s website (https://ir.discmedicine.com/).

Presentation Details:

The abstracts are now available through the ASH conference website. Pursuant to Disc Medicine practice, the clinical study abstracts published today contain previously presented data; new data and analyses are reserved for presentation at the conference.

Bitopertin:

**Type:**Oral presentation Publication Number: 326 Title: Inhibition of glycine transporter 1 reduces chronic inflammation and improves red blood cell health in a mouse model of erythropoietic protoporphyria (EPP) **Date / Time:**Saturday, December 12, 4:15 – 4:30pm EST **Presenting Author:**Yi Xiang, Ph.D.

Type: Poster presentation Publication Number: 4209 Title: APOLLO: Baseline characteristics of a phase 3, randomized, double-blind, placebo-controlled confirmatory study of bitopertin in adults and adolescents with erythropoietic protoporphyria or x-linked protoporphyria **Date / Time:**Sunday, December 13, 6:00 – 8:00pm EST **Presenting Author:**Amy Yeung, M.D., MPH, MSc

Type: Poster presentation Publication Number: 4621 Title: Glycine transporter 1 inhibition reduced porphyrinogen I isomers in a cellular model of cutaneous erythropoietic porphyria (CEP) **Date / Time:**Monday, December 14, 6:00 – 8:00pm EST **Presenting Author:**Yi Xiang, Ph.D.

Selcodebart (DISC-0974):

**Type:**Oral presentation Publication Number: 242 Title: RALLY-MF: Efficacy of a Phase 2 study of selcodebart (DISC-0974), an anti-hemojuvelin antibody, to treat anemia in myelofibrosis **Date / Time:**Saturday, December 12, 2:15 – 2:30pm EST **Presenting Author:**Naseema Gangat, M.B.B.S.

**Type:**Poster presentation Publication Number: 1123 Title: Anti-hemojuvelin monoclonal antibody reverses anemia and exerts disease-modifying effects in an adoptive T-cell transfer inflammatory bowel disease mouse model **Date / Time:**Saturday, December 12, 5:30 – 7:30pm EST **Presenting Author:**Julia Xu, Ph.D.

**Type:**Poster presentation Publication Number: 2287 Title: Anti-hemojuvelin monoclonal antibody increased hemoglobin and iron mobilization in combination with momelotinib in wild-type mice **Date / Time:**Sunday, December 13, 6:00 – 8:00pm EST **Presenting Author:**Julia Xu, Ph.D.

Type: Publication only Title: A systematic literature review to characterize the disease burden and unmet need of anemia associated with myelofibrosis

DISC-3405:

**Type:**Oral presentation Publication Number: 929 Title: Results from RESTORE-PV, an ongoing Phase 2 open-label study evaluating the safety and efficacy of DISC-3405 (a novel anti-TMPRSS6 monoclonal antibody) in participants with polycythemia vera **Date / Time:**Monday, December 14, 3:45 – 4:00pm EST **Presenting Author:**Naseema Gangat, M.B.B.S.

**Type:**Poster presentation Publication Number: 1180 Title: Preliminary results from DISC-3405-102: A phase 1b study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of DISC-3405 in participants with sickle cell disease **Date / Time:**Saturday, December 12, 5:30 – 7:30pm EST **Presenting Author:**Susanna Curtis, M.D., Ph.D.

About Disc Medicine

Disc Medicine is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. For more information, please visit www.discmedicine.com.

Disc Cautionary Statement Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, express or implied statements regarding Disc’s expectations with respect to: the next stages of its development programs; and projected timelines for the presentation of data across its portfolio. The use of words such as, but not limited to, “believe,” “expect,” “estimate,” “project,” “intend,” “future,” “potential,” “continue,” “may,” “might,” “plan,” “will,” “should,” “seek,” “anticipate,” or “could” or the negative of these terms and other similar words or expressions that are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on Disc’s current beliefs, expectations and assumptions regarding the future of Disc’s business, future plans and strategies, clinical results and other future conditions. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Disc may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and investors should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements as a result of a number of material risks and uncertainties including but not limited to: the adequacy of Disc’s capital to support its future operations and its ability to successfully initiate and complete clinical trials; the nature, strategy and focus of Disc; the difficulty in predicting the time and cost of development of Disc’s product candidates; Disc’s plans to research, develop and commercialize its current and future product candidates; the timing of initiation of Disc’s planned preclinical studies and clinical trials; the timing of the availability of data from Disc’s clinical trials; Disc’s ability to identify additional product candidates with significant commercial potential and to expand its pipeline in hematological diseases; the timing and anticipated results of Disc’s preclinical studies and clinical trials and the risk that the results of Disc’s preclinical studies and clinical trials may not be predictive of future results in connection with future studies or clinical trials and may not support further development and marketing approval; the content and timing of decisions made by the FDA and other regulatory authorities; and the other risks and uncertainties described in Disc’s filings with the Securities and Exchange Commission, including in the “Risk Factors” section of Disc’s Annual Report on Form 10-K for the year ended December 31, 2025, and in subsequent Quarterly Reports on Form 10-Q. Any forward-looking statement speaks only as of the date on which it was made. None of Disc, nor its affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as result of new information, future events or otherwise, except as required by law.

Media Contact

Peg Rusconi Deerfield Group [email protected]

Investor Relations Contact

Kevin Lui Precision AQ [email protected]

Disc Medicine

Privacy Preference Center

Privacy Preference Center

  • Your Privacy

  • Required Cookies

  • Functional and Analytics Cookies

  • Targeting and Social Media Cookies

Your Privacy

We and our affiliates and vendors use cookies and similar technologies to enhance site navigation, analyze site usage, and assist in our marketing efforts, including sharing data with third parties for advertising purposes. Click Accept All to accept all cookies, click Reject All to reject all but those cookies strictly necessary to the functioning of the site (required cookies) and to opt-out of the sale and sharing of your data, or click Manage Preferences to choose your cookie preferences. For more information, see our Privacy Notice. Cookie Notice.

Required Cookies

Always Active

These cookies are considered “required” for the regular operation and security of our Online Services, as well as for the provision of the services and products you request. Without these cookies, we will not be able to provide certain core features of our Online Services, such as loading images and allowing you to select your cookie preferences. These cookies do not store any personal information. For these cookies, we do not ask for your consent, but we do inform you about their presence on our Online Services.

Functional and Analytics Cookies

Functional and Analytics Cookies

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. They may be set by us or by third party service providers whose services we have added to our pages. These cookies may also measure how you interact with content on our Online Services, which helps us improve our Online Services and your experience. If you reject these cookies, then some or all of these services may not function properly, and we will not know when you have visited our site and will not be able to monitor its performance.

Targeting and Social Media Cookies

Targeting and Social Media Cookies

Targeting cookies may be set through our advertising partners and used by them to build a profile of your interests and show you more relevant advertisements on other sites. Disabling these types of cookies will not opt you out of being served ads. You may continue to receive non-targeted ads. Social Media cookies are capable of tracking your browser across other sites and building a profile of your interests. This may impact the content and messages you see on other websites you visit. Under certain laws, you have the right to opt out of the sale of your personal data to third parties. You also have the right to opt out of targeted advertising. You may exercise your right to opt out of the sale of your personal data and of targeted advertising via cookies and tracking technologies here, or by enabling a global opt-out signal as described below. If you opt out, we will not be able to offer you personalized ads, and we will stop sharing your personal data with social media partners. If you do not allow these cookies you may not be able to use or see these sharing tools. For more information on your privacy rights, contact us as indicated below.

Cookie List

Leg.Interest

checkbox label label

checkbox label label

checkbox label label

Clear

  • checkbox label label

Apply Cancel

Reject All Cookies Allow All Cookies

Powered by Onetrust

November 2, 2026

PDF Version

WATERTOWN, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that company management will participate in fireside chats at upcoming investor conferences:

  • Guggenheim 3rd Annual Healthcare Innovation Conference on Monday, November 9th at 10:30 a.m. ET

  • Stifel 2026 Healthcare Conference on Thursday, November 12th at 2:00 p.m. ET

  • UBS Global Biopharma Conference on Tuesday, November 17th at 3:40 a.m. ET / 8:40 a.m. GMT

  • Jefferies London Global Healthcare Conference on Wednesday, November 18th at 6:30 a.m. ET / 11:30 a.m. GMT

Disc management will be participating in investor meetings during the above conferences, as well as during the Truist BioPharma Symposium in New York on Thursday, November 12.

Live webcasts of the fireside chats will be available through the investor relations section of the Company's website at ir.discmedicine.com and an archived replay will be available after each event.

About Disc Medicine

Disc Medicine (NASDAQ:IRON) is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. For more information, please visit www.discmedicine.com.

Media Contact

Peg Rusconi Deerfield Group [email protected]

Investor Relations Contact

Kevin Lui Precision AQ [email protected]

Disc Medicine

Privacy Preference Center

Privacy Preference Center

  • Your Privacy

  • Required Cookies

  • Functional and Analytics Cookies

  • Targeting and Social Media Cookies

Your Privacy

We and our affiliates and vendors use cookies and similar technologies to enhance site navigation, analyze site usage, and assist in our marketing efforts, including sharing data with third parties for advertising purposes. Click Accept All to accept all cookies, click Reject All to reject all but those cookies strictly necessary to the functioning of the site (required cookies) and to opt-out of the sale and sharing of your data, or click Manage Preferences to choose your cookie preferences. For more information, see our Privacy Notice. Cookie Notice.

Required Cookies

Always Active

These cookies are considered “required” for the regular operation and security of our Online Services, as well as for the provision of the services and products you request. Without these cookies, we will not be able to provide certain core features of our Online Services, such as loading images and allowing you to select your cookie preferences. These cookies do not store any personal information. For these cookies, we do not ask for your consent, but we do inform you about their presence on our Online Services.

Functional and Analytics Cookies

Functional and Analytics Cookies

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. They may be set by us or by third party service providers whose services we have added to our pages. These cookies may also measure how you interact with content on our Online Services, which helps us improve our Online Services and your experience. If you reject these cookies, then some or all of these services may not function properly, and we will not know when you have visited our site and will not be able to monitor its performance.

Targeting and Social Media Cookies

Targeting and Social Media Cookies

Targeting cookies may be set through our advertising partners and used by them to build a profile of your interests and show you more relevant advertisements on other sites. Disabling these types of cookies will not opt you out of being served ads. You may continue to receive non-targeted ads. Social Media cookies are capable of tracking your browser across other sites and building a profile of your interests. This may impact the content and messages you see on other websites you visit. Under certain laws, you have the right to opt out of the sale of your personal data to third parties. You also have the right to opt out of targeted advertising. You may exercise your right to opt out of the sale of your personal data and of targeted advertising via cookies and tracking technologies here, or by enabling a global opt-out signal as described below. If you opt out, we will not be able to offer you personalized ads, and we will stop sharing your personal data with social media partners. If you do not allow these cookies you may not be able to use or see these sharing tools. For more information on your privacy rights, contact us as indicated below.

Cookie List

Leg.Interest

checkbox label label

checkbox label label

checkbox label label

Clear

  • checkbox label label

Apply Cancel

Reject All Cookies Allow All Cookies

Powered by Onetrust

Prompts

Disc Medicine, Inc. (ticker IRON), listed in United States.

Company History

Date Change Detail
Oct 3, 2022 Renamed GEMINI THERAPEUTICS, INC. /DE → DISC MEDICINE, INC.
Nov 27, 2020 Renamed FS DEVELOPMENT CORP. → GEMINI THERAPEUTICS, INC. /DE

ETFs Holding Disc Medicine, Inc.

ETF Weight in ETF Shares Market value As of
FMED 1.06% 6,926 $ 544.73K Aug 31, 2026
JDOC 0.69% 891 $ 68.224K Nov 17, 2026
SCDS 0.37% 440 $ 33.691K Nov 17, 2026
TMED 0.19% 600 $ 43.884K Jun 30, 2026
TMSL 0.17% 63,785 $ 4.665M Jun 30, 2026
JGRO 0.14% 162,438 $ 12.438M Nov 17, 2026
FFSM 0.12% 23,639 $ 1.82M Jul 31, 2026
ESSC 0.11% 511 $ 39.347K Jul 31, 2026
FSEG 0.10% 80 $ 5,851.20 Jun 30, 2026
RESM 0.06% 32 $ 2,340.48 Jun 30, 2026
DFAS 0.06% 233,000 $ 19.393M Nov 12, 2026
DFAC 0.01% 123,167 $ 10.251M Nov 12, 2026
MSSM 0.01% 855 $ 67.246K Aug 31, 2026
DCOR 0.01% 33,777 $ 2.811M Nov 12, 2026
DFAU 0.01% 9,014 $ 750.235K Nov 12, 2026
DFUS 0.00% 6,931 $ 576.867K Nov 12, 2026